Literature DB >> 30704663

Breast Cancer Screening: Why Can't Everyone Agree?

Veronica Jordan1, Muneeza Khan2, Donna Prill3.   

Abstract

Screening mammography and evolving treatments have improved mortality over the last 25 years. However, breast cancer remains the second leading cause of cancer-related mortality for women in the United States. There are several contradictory recommendations regarding breast cancer screening. Familiarity with these recommendations will allow physicians to counsel their patients and ensure well-informed shared decision making.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  BRCA1/2; Breast cancer; Clinical breast examination; Mammography; Screening; Self breast examination; Shared decision making

Mesh:

Year:  2018        PMID: 30704663     DOI: 10.1016/j.pop.2018.10.010

Source DB:  PubMed          Journal:  Prim Care        ISSN: 0095-4543            Impact factor:   2.907


  4 in total

1.  Variation in Breast Cancer Screening Recommendations by Primary Care Providers Surveyed in Wisconsin.

Authors:  Emily Nachtigal; Noelle K LoConte; Sarah Kerch; Xiao Zhang; Amanda Parkes
Journal:  J Gen Intern Med       Date:  2020-06-03       Impact factor: 5.128

Review 2.  Cancer Progress and Priorities: Breast Cancer.

Authors:  Serena C Houghton; Susan E Hankinson
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2021-05       Impact factor: 4.090

3.  A comprehensive comparison of circulating tumor cells and breast imaging modalities as screening tools for breast cancer in Chinese women.

Authors:  Xuan Shao; Xiaoyan Jin; Zhigang Chen; Zhigang Zhang; Wuzhen Chen; Jingxin Jiang; Zhen Wang; Ying Cui; Wan-Hung Fan; Ke Wang; Xiuyan Yu; Jian Huang
Journal:  Front Oncol       Date:  2022-08-01       Impact factor: 5.738

4.  Enhancing the Screening Efficiency of Breast Cancer by Combining Conventional Medical Imaging Examinations With Circulating Tumor Cells.

Authors:  Yang Gao; Wan-Hung Fan; Chaohui Duan; Wenhe Zhao; Jun Zhang; Xixiong Kang
Journal:  Front Oncol       Date:  2021-05-19       Impact factor: 6.244

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.